The investment-grade notes are due 2031, 2035 and 2055

Davis Polk advised the representatives of the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $400 million principal amount of 5.050% senior notes due 2031, $650 million principal amount of 5.750% senior notes due 2035 and $700 million principal amount of 6.450% senior notes due 2055. Proceeds of the offering will be used, together with cash on hand, to retire in full, by redemption or payment at maturity, the existing 4.050% senior notes due 2025, including the payment of all accrued and unpaid interest, and any remainder for working capital and other general corporate purposes.

Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. Biogen has a broad portfolio of medicines to treat multiple sclerosis, introduced the first approved treatment for spinal muscular atrophy, co-developed treatments to address a defining pathology of Alzheimer’s disease and launched the first approved treatment to target a genetic cause of amyotrophic lateral sclerosis. Biogen markets the first and only drug approved in the United States, the EU and certain international markets for the treatment of Friedreich ataxia in adults and adolescents aged 16 years and older.

The Davis Polk capital markets team included partner Michael Kaplan and associate Benjamin Guillon. Partner David R. Bauer and associate Gabrielle Mazero provided intellectual property advice. The tax team included partner Aliza Slansky and associate Hunter P. Shaw. All members of the Davis Polk team are based in the New York office.

Copy link to share post